Repligen Corporation Engages Investors at Upcoming Conferences
Repligen Corporation (NASDAQ:RGEN), a notable player in the life sciences sector, is preparing to engage with investors at key conferences this month. Based in Waltham, Massachusetts, the company is recognized for its innovation and leadership in bioprocessing technology.
Upcoming Investor Conferences
This May, Repligen is set to participate in two significant investor conferences that offer great opportunities for dialogue regarding their latest advancements.
RBC Capital Markets’ Global Healthcare Conference
The first event on the calendar is the RBC Capital Markets’ 2025 Global Healthcare Conference, taking place in New York on May 20-21. Jason K. Garland, the Chief Financial Officer, is set to lead an analyst-led discussion on May 20 at 3:35 p.m. ET. This presentation will offer valuable insights into Repligen's strategies and future directions.
Craig-Hallum’s Annual Institutional Investor Conference
Following the RBC conference, on May 28, Repligen will participate in the Craig-Hallum’s 22nd Annual Institutional Investor Conference in Minneapolis. Here, Mr. Garland will engage in one-on-one meetings with investors, further discussing the company’s initiatives in the bioprocessing arena.
Webcast Information
For those unable to attend, a live webcast of the RBC conference presentation will be available on Repligen’s Investor Relations website. After the event, a replay will be accessible for a limited time, ensuring that interested parties can catch up on the presentations and discussions that occurred.
Corporate Overview of Repligen Corporation
Repligen Corporation has carved out a niche in the life sciences market by developing and commercializing innovative bioprocessing technologies. Their mission is to inspire advancements in bioprocessing for clients ranging from biopharmaceutical developers to contract manufacturing organizations (CDMOs) globally.
The company focuses on several key areas including Filtration, Fluid Management, Chromatography, Process Analytics, and Proteins. With the majority of manufacturing operations based in the United States, Repligen also maintains significant facilities in countries like Estonia, France, Germany, Ireland, the Netherlands, and Sweden, illustrating its commitment to global service and presence.
For more information about Repligen Corporation, exploring their technology offerings or investor opportunities, interested parties are encouraged to visit their official website and connect professionally through platforms like LinkedIn.
Company Contact Information
Those with inquiries or seeking further engagement can reach out to Jacob Johnson, VP of Investor Relations. He can be contacted at (781) 419-0204 or via email at investors@repligen.com for assistance.
Frequently Asked Questions
What is Repligen Corporation's core business focus?
Repligen Corporation specializes in developing innovative bioprocessing technologies that enhance the efficiency of manufacturing biological drugs.
When will the upcoming investor conferences take place?
The RBC Capital Markets’ conference is on May 20-21, and the Craig-Hallum conference is on May 28.
Is there a way to access the conference presentation online?
Yes, a live webcast of the RBC conference presentation will be available on Repligen’s Investor Relations website, along with a replay afterward.
Who is leading the discussions at the conferences?
Jason K. Garland, the Chief Financial Officer of Repligen Corporation, will lead these discussions.
How can I get in touch with Repligen for more information?
For inquiries, you can contact Jacob Johnson at (781) 419-0204 or via email at investors@repligen.com.
